A Phase 3 interventional study of Susu Xiao'er Zhike Granules and Extremely-low dose Susu Xiao'er Zhike Granules in Cough, sponsored by Tasly Pharmaceutical Group Co., Ltd. Not yet recruiting at 19 sites in China. Open to participants aged 6 Years to 13 Years. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Cough with a site in China — 7 open to participants now, 8 under way, 3 of them phase 3. Cough · China.
Among the 30 studies in Cough with a site in China, this one is the 4th largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 3, and was the 22nd registered.
429 studies on the registry are indexed under Cough; 69 are open to participants now.
Browse Cough studies →7 of the 30 studies in Cough with a site in China are open now. Recruiting first, the newest first:
Shiyou Wei · Sites in China
Ages 18–99
The University of Hong Kong · Sites in China, Hong Kong
Ages 18+
GlaxoSmithKline · Sites in China
Ages 18–80
Shanghai Changzheng Hospital · Sites in China
Ages 18–60
Ruijin Hospital · Sites in China
Ages 40+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cough studies recruiting now, 20 (43%) set no upper age limit and 14 (30%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 6 Years to 13 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 6 · Phase 4 3
First in 2014; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 80 across 321 interventional studies indexed under Cough.
Median enrollment 200 across the 24 interventional studies, 383 across the 6 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Tasly Pharmaceutical Group Co., Ltd, one of the names counted as China Resources Pharmaceutical Group Limited. Under that name alone:
Tasly Pharmaceutical Group Co., Ltd is the lead sponsor of 32 studies on the registry; 17 are open to participants now.
China Resources Pharmaceutical Group Limited has 2 studies filed under Cough — fewer than ten, so there is no comparison to draw.
4 of the studies in Cough with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06773117Phase 3Tasly Pharmaceutical Group Co., LtdPhase III Trial of Susu Zhike Granules in Children With Cold-cough Syndrome for Acute Cough Treatment | 2027-05-31 |
| NCT07650084Phase 3GlaxoSmithKlineA 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension | 2027-08-27 |
| NCT07315672The University of Hong KongAcupressure for Cough in Lung Cancer Survivors | 2026-12 |
| NCT07778953Shiyou Wei90% Effective Infusion Time of Sufentanil to Prevent Induction Cough: A Biased Coin Sequential Study | 2026-12-25 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Cough with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To confirm the effect of Susu Xiaoer Zhike granules in treating cough caused by common cold (wind-cold cough Syndromes) in children aged 6\~13 years, shortening the course of disease and improving symptoms.
Susu used to be a clinical experienced Chinese herb formula for treating acute cough caused by common cold. The ingredients includes Hua Ju Hong, Qiao Rui Su, Zi Su Ye, Jie Geng, Gan Cao,which relieving cold and cough, resolving phlegm in traditional Chinese medicine theory. This prescription was used for a long time in clinical for treatingacute cough caused by common cold as an herb formula. To standardize the quality and make it easier to take, The investigators reproduced it into a patent medicine and design this trial for evaluating it.
The phase II clinical study of Susu Xiaoer Zhike Granules was carried out in the past, and the results showed that the use of Susu Xiaoer Zhike granules (containing 20.25g of raw drug) in the high dose group could significantly improve the clinical recovery rate (P\<0.05) and shorten the clinical recovery time (P\<0.05) in children aged 6 to 14 years (\< 14 years) caused by common cold (wind-cold cough). And good security. Based on the effectiveness and safety results of the phase II clinical study, this study intends to select the high-dose group of the phase II clinical study (containing 20.25g of raw drug) as the experimental group of the phase III clinical study, and the extremely-low dose group of the phase II clinical study as the control group. To conduct confirmatory clinical studies on cough (wind-cold cough) caused by common cold in children aged 6 to 13 years (6 years ≤ age \< 14 years).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Susu Xiao'er Zhike Granules 1 bag
Drug: Susu Xiao'er Zhike Granules
Extremely-low dose Susu Xiao'er Zhike Granules 1 bag
Drug: Extremely-low dose Susu Xiao'er Zhike Granules
Susu Xiao'er Zhike Granules 1 bag(7g granule per bag,contains 20.25 g crude herbs), twice a day for five days
Extremely-low dose Susu Xiao'er Zhike Granules 1 bag (7g granule per bag,contains 1.01 g crude herbs), twice a day for five days
Cough disappearance rate
Cough symptom scores were recorded at baseline and daily after treatment and evaluated at the end of treatment (Patients whose cough did not disappear were followed up for 24 hours).
Time frame: 5 days
Cough symptom score
Baseline and post-treatment were recorded daily, and diachronic changes were evaluated at the end of treatment.
Time frame: Baseline, 1, 2, 3, 4, and 5 days
VAS score of cough symptoms
Baseline and post-treatment were recorded daily, and diachronic changes were evaluated at the end of treatment.
Time frame: Baseline, 1, 2, 3, 4, and 5 days
Time to disappearance of cough
Cough symptom scores were recorded at baseline and daily after treatment and evaluated at the end of treatment (Patients whose cough did not disappear were followed up for 24 hours).
Time frame: 5 days
Onset time of cough
Cough VAS score were recorded at baseline and daily after treatment and evaluated at the end of treatment
Time frame: 5 days
Disease cure rate
Cold symptoms were recorded and evaluated at baseline and after 5 days of treatment.
Time frame: 5 days
PAC-QoL scale score
Baseline and 5 days of treatment were recorded and evaluated.
Time frame: 5 days
Effective rate of TCM syndrome
Baseline and 5 days of treatment were recorded and evaluated.
Time frame: 5 days
The rate of disappearance of individual symptoms
Baseline and 5 days of treatment were recorded and evaluated.
Time frame: 5 days
Incidence OF COMPLICATIONS
Post-treatment records were recorded and end-of-treatment evaluations were performed.
Time frame: 5 days
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for May 2027, 20 months later.
Of 18 phase 3 interventional studies under Cough, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tasly Pharmaceutical Group Co., Ltd →